| Stage | ECG | % of rev | MYRG | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $1.2B | 100.00% | $1.3B | 100.00% | MYRG ×1.02 |
| Gross profit | $183M | 14.85% | $171M | 13.60% | ECG +1.3pp |
| Operating income | $112M | 9.08% | $85M | 6.76% | ECG +2.3pp |
| Pre-tax income | $110M | 8.93% | $82M | 6.54% | ECG +2.4pp |
| Net income | $84M | 6.81% | $60M | 4.77% | ECG +2.0pp |
| Stage | ECG | MYRG | Gap · A − B |
|---|---|---|---|
| Revenue | $1.2B100.00% | $1.3B100.00% | MYRG ×1.02 |
| Gross profit | 14.85%$183M | 13.60%$171M | ECG +1.3pp |
| Operating income | 9.08%$112M | 6.76%$85M | ECG +2.3pp |
| Pre-tax income | 8.93%$110M | 6.54%$82M | ECG +2.4pp |
| Net income |
| 6.81%$84M |
| 4.77%$60M |
| ECG +2.0pp |
No disclosed counterparties: MYRG.
None